Sandoz Group Valuation
Is SDZZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SDZZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SDZZ (CHF32.65) is trading below our estimate of fair value (CHF106.57)
Significantly Below Fair Value: SDZZ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SDZZ?
Other financial metrics that can be useful for relative valuation.
| What is SDZZ's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$15.57b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 23.7x |
| PEG Ratio | 6.9x |
Price to Sales Ratio vs Peers
How does SDZZ's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.9x | ||
HIK Hikma Pharmaceuticals | 1.8x | 3.9% | UK£4.2b |
DPH Dechra Pharmaceuticals | 5.8x | 7.9% | UK£4.4b |
GSK GSK | 2x | 4.7% | UK£62.4b |
INDV Indivior | 1.9x | 10.3% | UK£1.7b |
SDZZ Sandoz Group | 1.6x | 4.9% | CHF 14.0b |
Price-To-Sales vs Peers: SDZZ is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does SDZZ's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?
Price-To-Sales vs Industry: SDZZ is good value based on its Price-To-Sales Ratio (1.6x) compared to the European Pharmaceuticals industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is SDZZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | 3.7x |
Price-To-Sales vs Fair Ratio: SDZZ is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (3.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 32.65 | CHF 36.15 +10.7% | 11.7% | CHF 43.21 | CHF 27.62 | n/a | 14 |
| Jun ’25 | CHF 32.25 | CHF 36.38 +12.8% | 12.7% | CHF 44.13 | CHF 28.20 | n/a | 15 |
| May ’25 | CHF 31.19 | CHF 35.17 +12.8% | 14.1% | CHF 44.76 | CHF 26.59 | n/a | 15 |
| Apr ’25 | CHF 27.14 | CHF 34.55 +27.3% | 15.3% | CHF 45.80 | CHF 26.16 | n/a | 14 |
| Mar ’25 | CHF 27.95 | CHF 33.56 +20.1% | 14.1% | CHF 44.62 | CHF 26.79 | n/a | 14 |
| Feb ’25 | CHF 28.52 | CHF 33.19 +16.4% | 14.0% | CHF 44.08 | CHF 26.46 | n/a | 14 |
| Jan ’25 | CHF 27.10 | CHF 31.33 +15.6% | 18.7% | CHF 45.98 | CHF 24.58 | n/a | 12 |
| Dec ’24 | CHF 25.75 | CHF 31.58 +22.6% | 18.5% | CHF 45.84 | CHF 25.20 | n/a | 12 |
| Nov ’24 | CHF 24.00 | CHF 35.28 +47.0% | 27.7% | CHF 59.09 | CHF 26.23 | n/a | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.